📢 #ESMO26 concomitant paper - Perioperative pembrolizumab or pbo + neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for ci

Annals of Oncology· @Annals_Oncology · X·2026-10-23 19:45· 2 days agoScore70

Body · original

📢 #ESMO26 concomitant paper - Perioperative pembrolizumab or pbo + neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study.
🔗https://shorturl.at/6wrs1
@DrChrisHoimes

898 views · 9 likes · 3 reposts · 0 replies

Conference abstracts

4735Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study

https://esmocongress.esmo.org

Source: Annals of Oncology · x.com